Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.
UCSF Neuroimmunology Seminar
[Recent prognosis on etiology and pathophysiology of multiple sclerosis].
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.
Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors.
Mechanisms of Immune Modulation By Mesenchymal Stromal Cells and Clinical Translation.
Hyaluronan oligosaccharides perturb lymphocyte slow rolling on brain vascular endothelial cells: Implications for inflammatory demyelinating disease.
A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis.
A Surprisingly Low Prevalence of Demonstrable Stress Urinary Incontinence and Pelvic Organ Prolapse in Women with Multiple Sclerosis Followed at a Tertiary Neurogenic Bladder Clinic.
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses.
Pilates exercise training vs. physical therapy for improving walking and balance in people with multiple sclerosis: A randomized controlled trial.
Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease.
Impairment of endothelial function in patients with multiple sclerosis.
Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis.
Which immune cells matter? The immunopathogenesis of multiple sclerosis.
Copaiba Oil Suppresses Inflammatory Cytokines in Splenocytes of C57Bl/6 Mice Induced with Experimental Autoimmune Encephalomyelitis (EAE).
[Biomarkers in neuromyelitis optica].
Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis.
Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.
2-BFI ameliorates EAE-induced mouse spinal cord damage: Effective therapeutic time window and possible mechanisms.
The first 10 years with multiple sclerosis: The longitudinal course of daily functioning.
Brain-Derived Neurotrophic Factor in Neuroimmunology: Lessons Learned from Multiple Sclerosis Patients and Experimental Autoimmune Encephalomyelitis Models.
Patient autonomy in multiple sclerosis - Possible goals and assessment strategies.
Gut microbiome and the risk factors in central nervous system autoimmunity.
Multiple sclerosis fatigue relief by bilateral somatosensory cortex neuromodulation.

Pages